On Tuesday, Bharat Biotech informed that it has inked a pact with Precisa Medicamentos for the supply of its indigenously produced Covid-19 vaccine ‘Covaxin’ to Brazil. In a statement, the company stated that the supplies of Covaxin will be prioritized for public market, by means of direct procurement by Brazil government. It further added that the supplies of Covaxin to private market would be based upon receipt of market authorization from ANVISA, Brazilian regulatory authority. As per a press release by the Hyderabad-based pharma company, the team met Dr Krishna Ella, Bharat Biotech chief, on January 7 and January 8 at its facility in Hyderabad’s Genome Valley. Also, André Aranha Corrêa do Lago, Ambassador of Brazil to India, joined the discussion virtually.
BharatBiotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV) is indigenously developing Covaxin. As per the firm, the indigenous, inactivated vaccine is developed and made in BharatBiotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility. Since the pandemic began, Brazil has registered more than 8 million cases of the virus. On the other hand, the official death toll has risen over 203,000. This is the world’s second-deadliest coronavirus outbreak. Brazil has inked pacts to get other COVID-19 vaccines. To speed up the vaccine rollout, authorities are facing growing pressure. Apart from this, many Latin countries such as Chile and Argentina have already started immunizations.
In the meantime, on 3 January, India’s drugs regulator gave its approval to Oxford COVID-19 vaccine Covishield, made by the Serum Institute. Also, it gave approval to indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country. From 16 January 2021, the mega vaccination drive in India is slated to begin.